NCT07223424 2026-04-16
PSI-Immune
University of Pittsburgh
Phase 2 Recruiting
Clinical Trials
51 trialsNCT07166406 2026-04-08
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NRG Oncology
Phase 3 Recruiting
NCT07075120 2026-03-31
Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer
University of Hawaii
Phase 1 Not yet recruiting
NCT06354387 2026-03-19
Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1
China Medical University Hospital
Phase 1 Completed
NCT04380545 2026-03-06
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT04785287 2026-03-03
Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT07376707 2026-01-29
TGI5
Hefei TG ImmunoPharma Co., Ltd.
Phase 1 Recruiting
NCT04658147 2025-12-18
Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT04157985 2025-12-11
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Phase 3 Completed
NCT06265285 2025-12-04
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Mayo Clinic
Phase 2 Recruiting
NCT04050462 2025-10-16
Nivolumab Combined With BMS-986253 in HCC Patients
NYU Langone Health
Phase 2 Terminated
NCT05199285 2025-10-03
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab
Academic and Community Cancer Research United
Phase 2 Terminated
NCT04912765 2025-09-23
Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
National Cancer Centre, Singapore
Phase 2 Recruiting
NCT07053202 2025-07-08
TACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma
The First Hospital of Hebei Medical University
Phase NA Completed
NCT03655002 2025-06-17
IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT04472767 2025-04-30
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
University of California, Irvine
Phase 2 Recruiting
NCT04268888 2025-02-26
TACE-3
The Clatterbridge Cancer Centre NHS Foundation Trust
Phase 2/3 Suspended
NCT03190174 2025-02-17
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
Sarcoma Oncology Research Center, LLC
Phase 1/2 Completed
NCT03439891 2025-02-11
Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer
University of California, San Francisco
Phase 2 Completed
NCT04114136 2025-02-10
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
University of Pittsburgh
Phase 2 Recruiting
NCT03695952 2025-01-28
A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors
Asan Medical Center
Active not recruiting
NCT04123379 2025-01-17
Neoadjuvant Nivolumab with CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)
Icahn School of Medicine at Mount Sinai
Phase 2 Active not recruiting
NCT03033446 2025-01-06
Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma
National Cancer Centre, Singapore
Phase 2 Active not recruiting
NCT05302921 2025-01-01
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
Children's National Research Institute
Phase 2 Completed
NCT03299946 2024-09-03
Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT04170556 2024-09-03
GOING
Fundacion Clinic per a la Recerca Biomédica
Phase 1/2 Completed
NCT03630640 2024-07-31
NIVOLEP
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT04823403 2024-07-26
HIPANIV
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Recruiting
NCT03510871 2024-07-08
Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)
National Health Research Institutes, Taiwan
Phase 2 Completed
NCT04627012 2024-03-06
Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Completed
NCT03812562 2024-02-21
Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection
Northwestern University
Phase EARLY_PHASE1 Terminated
NCT03695250 2023-08-22
BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer
University of California, Davis
Phase 1/2 Terminated
NCT03572582 2023-07-20
IMMUTACE
AIO-Studien-gGmbH
Phase 2 Completed
NCT03222076 2023-07-10
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03841201 2023-05-12
Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT05039736 2023-05-12
A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT05471674 2023-02-01
Neoadjuvant Anti-PD1 in HCC
The University of Hong Kong
Phase 2 Completed
NCT03781960 2022-12-14
Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma
Abramson Cancer Center at Penn Medicine
Phase 2 Terminated
NCT03682276 2022-12-13
PRIME-HCC
Imperial College London
Phase 1/2 Unknown
NCT04310709 2022-12-06
RENOBATE
Asan Medical Center
Phase 2 Completed
NCT05281926 2022-03-16
A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients
National Taiwan University Hospital
Phase 1 Unknown
NCT05233358 2022-02-10
HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure
The Central Hospital of Lishui City
Phase NA Unknown
NCT04233840 2022-01-27
P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma
National Taiwan University Hospital
Phase 1/2 Unknown
NCT02837029 2022-01-25
Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer
Northwestern University
Phase 1 Completed
NCT03203304 2021-06-10
Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer
University of Chicago
Phase 1 Terminated
NCT03380130 2020-11-04
NASIR-HCC
Clinica Universidad de Navarra, Universidad de Navarra
Phase 2 Completed
NCT03511222 2020-07-29
Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
Washington University School of Medicine
Phase 1 Terminated
NCT04044651 2020-01-09
Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection
Sun Yat-sen University
Phase 2/3 Withdrawn
NCT03382886 2019-12-12
NUANCE
University of Utah
Phase 1 Terminated